| Chief Investigator: |
Professor Nicholas James |
| Sponsor: |
University of Birmingham |
| Funders: |
Cancer Research UK |
| Disease Site: |
Bladder Cancer |
| Trial Type: |
Chemoradiotherapy / Phase II |
| Status: |
Closed, 6th September 2018 |
| UKCRN Study ID: (if applicable) |
7949 |
| Recruitment start date: |
06 July 2012 |
| Recruitment end date: |
31st October 2016 |
| CRCTU Trial Management Team: |
Team A |
| Trial E-mail Address: |
tuxedo@trials.bham.ac.uk |
- View trial summary document [.pdf]
Muscle invasive bladder cancer describes bladder cancer which has grown into the muscle layer of the bladder wall. This is usually treated with chemotherapy and radiotherapy.
The trial is looking at combining radiotherapy with a monoclonal antibody called cetuximab given alongside standard chemotherapy drugs. Following successful phase I results where a combination of the chemotherapy drugs, 5-FU and mitomycin C, were delivered alongside cetuximab and radiotherapy, this treatment regimen is now being tested in a phase II setting to find out if it works better at preventing bladder recurrence than the current standard treatment.
Please note that the trials team cannot give individual’s clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible